Regeneron Pharmaceuticals (NASDAQ:REGN) Raised to Strong-Buy at Wolfe Research

Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by analysts at Wolfe Research to a “strong-buy” rating in a research report issued to clients and investors on Thursday,Zacks.com reports.

Other analysts also recently issued research reports about the company. Leerink Partners reiterated a “market perform” rating and set a $1,077.00 price target (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a research report on Tuesday, September 24th. Morgan Stanley reduced their target price on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. Cantor Fitzgerald reiterated a “neutral” rating and issued a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 23rd. Guggenheim raised their target price on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. Finally, JPMorgan Chase & Co. lowered their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a report on Thursday, October 24th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $1,099.55.

Regeneron Pharmaceuticals Stock Down 3.3 %

Regeneron Pharmaceuticals stock traded down $25.70 during midday trading on Thursday, hitting $756.81. 1,374,549 shares of the stock were exchanged, compared to its average volume of 530,457. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $83.17 billion, a price-to-earnings ratio of 18.73, a price-to-earnings-growth ratio of 3.04 and a beta of 0.15. Regeneron Pharmaceuticals has a 52-week low of $753.69 and a 52-week high of $1,211.20. The business’s 50-day moving average price is $985.21 and its 200-day moving average price is $1,032.97.

Insider Activity at Regeneron Pharmaceuticals

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the transaction, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. This trade represents a 27.07 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 7.48% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Quent Capital LLC boosted its position in shares of Regeneron Pharmaceuticals by 5.1% during the 1st quarter. Quent Capital LLC now owns 390 shares of the biopharmaceutical company’s stock valued at $375,000 after acquiring an additional 19 shares during the last quarter. Acadian Asset Management LLC raised its position in Regeneron Pharmaceuticals by 37.2% during the 1st quarter. Acadian Asset Management LLC now owns 62,141 shares of the biopharmaceutical company’s stock valued at $59,794,000 after purchasing an additional 16,856 shares in the last quarter. Jacobi Capital Management LLC lifted its stake in Regeneron Pharmaceuticals by 1.8% in the first quarter. Jacobi Capital Management LLC now owns 1,139 shares of the biopharmaceutical company’s stock worth $1,096,000 after acquiring an additional 20 shares during the period. Covestor Ltd boosted its stake in shares of Regeneron Pharmaceuticals by 7.4% during the first quarter. Covestor Ltd now owns 202 shares of the biopharmaceutical company’s stock valued at $195,000 after purchasing an additional 14 shares in the last quarter. Finally, O Shaughnessy Asset Management LLC raised its position in shares of Regeneron Pharmaceuticals by 17.5% in the 1st quarter. O Shaughnessy Asset Management LLC now owns 6,920 shares of the biopharmaceutical company’s stock worth $6,660,000 after acquiring an additional 1,030 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.